BOTULINUM TOXIN A FOR AXILLARY HYPERHIDROSIS (EXCESSIVE SWEATING)

MARC HECKMANN, M.D., ANDRÉS O. CEBALLOS-BAUMANN, M.D., AND Gerd Plewig, M.D.,
FOR THE HYPERHIDROSIS STUDY GROUP*

ABSTRACT

Background  Treatment of primary focal hyperhidrosis is often unsatisfactory. Botulinum toxin A can stop excessive sweating by blocking the release of acetylcholine, which mediates sympathetic neurotransmission in the sweat glands.

Methods  We conducted a multicenter trial of botulinum toxin A in 145 patients with axillary hyperhidrosis. The patients had rates of sweat production greater than 50 mg per minute and had had primary axillary hyperhidrosis that was unresponsive to topical therapy with aluminum chloride for more than one year. In each patient, botulinum toxin A (200 U) was injected into one axilla, and placebo was injected into the other in a randomized, double-blind manner. (The units of the botulinum toxin A preparation used in this study are not identical to those of other preparations.) Two weeks later, after the treatments were revealed, the axilla that had received placebo was injected with 100 U of botulinum toxin A. Changes in the rates of sweat production were measured by gravimetry.

Results  At base line, the mean (±SD) rate of sweat production was 192±136 mg per minute. Two weeks after the first injections the mean rate of sweat production in the axilla that received botulinum toxin A was 24±27 mg per minute, as compared with 144±113 mg per minute in the axilla that received placebo (P<0.001). Injection of 100 U into the axilla that had been treated with placebo reduced the mean rate of sweat production in that axilla to 32±39 mg per minute (P<0.001). Twenty-four weeks after the injection of 100 U, the rates of sweat production (in the 136 patients in whom the rates were measured at that time) were still lower than base-line values, at 67±66 mg per minute in the axilla that received 200 U and 65±64 mg per minute in the axilla that received placebo and 100 U of the toxin. Treatment was well tolerated; 98 percent of the patients said they would recommend this therapy to others.

Conclusions  Intradermal injection of botulinum toxin A is an effective and safe therapy for severe axillary hyperhidrosis. (N Engl J Med 2001;344:488-93.)

Copyright © 2001 Massachusetts Medical Society.

In humans, sweating is induced by heat or exercise and is part of thermoregulation. Primary hyperhidrosis is defined as excessive, uncontrollable sweating without any discernible cause. It most commonly involves the axillae, palms, and soles. Severely affected patients have skin maceration and secondary microbial infections; their clothes may be drenched, especially from axillary hyperhidrosis; and they may be socially stigmatized. The diagnosis is based on the patient’s history and visible signs of excessive sweating. The extent of hyperhidrosis can be measured gravimetrically as the rate of sweat production (expressed in milligrams per minute).

Therapies that have been shown to reduce the rate of sweat production include iontophoresis, topical application of aluminum chloride, and administration of anticholinergic agents and beta-blockers. For axillary hyperhidrosis, however, iontophoresis is cumbersome: several times a week, wet sponges wrapped around metal electrodes must be inserted into each armpit for 20 minutes and a low-voltage current applied to the skin, producing a stinging sensation. Application of aluminum chloride often must be discontinued because of skin irritation. Anticholinergic agents and beta-blockers may have substantial side effects.

In certain instances, the surgical removal of sweat glands may be considered. Sympathectomy is of limited benefit for isolated axillary hyperhidrosis. Recently, the intradermal injection of botulinum toxin A has been shown to be effective in patients with gustatory sweating (pathologic sweating in response to the tasting of food, also known as Frey’s syndrome) and those with axillary sweating. Botulinum toxin A blocks neuronal acetylcholine release at the neuromuscular junction and in cholinergic autonomic neurons. It has been used extensively for decreasing muscle tone in patients with focal dystonia, spasticity, achalasia, or chronic anal fissures. Data on its use for hyperhidrosis are restricted to reports on small series of patients at specialized centers. We conducted a multicenter trial of botulinum toxin A in patients with axillary hyperhidrosis.

METHODS

Patients

The study was conducted between January 1999 and March 2000. It was approved by the ethics committee of Ludwig Maximilians University (Munich, Germany) as well as the ethics committees of the participating medical centers. Patients were selected according to the following criteria: excessive axillary perspiration for more than one year; a rate of sweat production greater than 50 mg per minute on at least two occasions, as measured by a standardized gravimetrical method.

From the Department of Dermatology, Ludwig-Maximilians-Universität (M.H., G.P.), and the Department of Neurology, Technische Universität München (A.O.C.-B.) — both in Munich, Germany. Address reprint requests to Dr. Heckmann at Dermatologische Klinik, Ludwig-Maximilians-Universität, Frauenlobstr. 9–11, 80337 Munich, Germany, or at heckmann@derma.med.uni-muenchen.de.

*Other members of the Hyperhidrosis Study Group are listed in the Appendix.
gravimetric procedure; and failure of 10 percent or 20 percent solutions of topical aluminum chloride, applied daily before bed for four weeks, to control sweating. Exclusion criteria were the presence of neuromuscular disease; organic causes of hyperhidrosis, such as hyperthyroidism; concomitant therapy for hyperhidrosis; intake of drugs that may affect muscle tone or the autonomic nervous system; pregnancy; and cancer. All the patients provided written informed consent.

After enrollment, the patients underwent gravimetric assessments on two separate occasions before treatment was to begin. We initially enrolled 158 patients. Twelve of these patients were excluded after the second gravimetric assessment because they did not meet the inclusion criteria (in most cases, because their rate of sweat production was lower than the required rate); one of these patients had elevated serum levels of thyroid hormone. One additional patient withdrew from the study because he moved to a distant location. In total, we studied 145 patients from 24 centers, all of whom completed 14 weeks of follow-up; 136 patients completed 26 weeks of follow-up.

Measurement of Sweat Production

Gravimetric measurements were performed, as described previously, on at least two occasions before treatment and at every subsequent visit. Measurements were made after the patient had rested for 15 minutes at a room temperature of 21°C to 25°C. Briefly, a filter paper (Melitta, Minden, Germany) was weighed on a high-precision laboratory scale (accuracy, ±0.5 mg) (Sartorius, Hamburg, Germany), placed in the arm pits for 60 seconds, and then weighed again. The rate of sweat production (in milligrams per minute) was then calculated. Before treatment, the actively sweating areas were determined by means of Minor’s iodine–starch test and then outlined with a waterproof marker. Ten evenly distributed points within each area were then marked as prospective sites for injection.

Study Design and Randomization

The sponsor of the study, Ipsen-Pharma (Ettlingen, Germany), supplied botulinum toxin A (Dysport) but did not design the study; did not collect, analyze, or interpret the data; and did not write any part of this report. Units of botulinum toxin A in this report refer to the units used in other preparations of botulinum toxin A.

The first dose of botulinum toxin A (200 U) was injected intradermally into one axilla and placebo was injected into the other axilla in a randomized, double-blind fashion, as follows. For each patient, two vials, each labeled either “right axilla” or “left axilla,” were prepared by Penn Pharmaceuticals Clinical Studies Supply Unit (Gwent, United Kingdom) according to a computerized randomization scheme. One vial contained botulinum toxin A (500 U, stabilized with 0.125 mg of human albumin and 2.5 mg of lactose), and the other contained placebo (0.125 mg of human albumin and 2.5 mg of lactose); they were prepared as identical lyophilized pellets. The treating physician dissolved the pellet contained in each vial in 5 ml of 0.9 percent sodium chloride solution and injected 10 0.2-ml fractions of the resulting solution (a total of 200 U of botulinum toxin A or placebo) into the respective axilla. Neither the treating physician nor the patient knew which axilla received botulinum toxin A and which received placebo. The treatment-allocation code for each patient was kept in a sealed envelope and revealed on day 14 after the injections, after the treatment results had been evaluated gravimetrically. The contents of a third vial, labeled “second injection,” which contained 500 U of botulinum toxin A, was then dissolved in 5 ml of sterile sodium chloride, and 10 0.1-ml fractions of the resulting solution (for a total of 100 U of botulinum toxin A) were then injected into the axilla that had previously been treated with placebo.

Questionnaire

On day 28 after the injection of 200 U of botulinum toxin A or placebo, patients were asked the following questions: Are you satisfied with this treatment (completely satisfied, satisfied, partially satisfied, or not satisfied)? How would you describe your tolerance of this treatment (excellent, good, fair, or poor)? Would you recommend this treatment to others (in all cases, in most cases, in some cases, or not at all)?

Statistical Analysis

Statistical analysis was performed with the SAS software package (version 6.12, SAS Institute, Cary, N.C.). Absolute values for the rate of sweat production were the primary outcome. The rate of sweat production in one axilla was compared with that in the other with use of paired t-tests. The relative reduction in sweating was computed as the percentage difference between the pretreatment (base-line) and post-treatment rates of sweat production; for instance, a change in the rate of sweat production from 160 mg per minute to 40 mg per minute was a 75 percent reduction. The Wilcoxon–Mann–Whitney test was used to compare the reduction in sweat production after the injection of 200 U of botulinum toxin A with the reduction after the injection of 100 U. The McNemar test was used for pairwise comparisons of 200 U and 100 U of botulinum toxin A and placebo with respect to rates of response and treatment failure. All statistical tests were two-sided. The analysis was based on data for all patients who received both doses of botulinum toxin A.

RESULTS

The base-line characteristics of the 145 patients who completed 14 weeks of follow-up are summarized in Table 1. Gravimetrically measured rates of sweat production ranged from 50 to 1000 mg per minute (mean, 192±136; median, 154), but the mean difference between the rates in the two axillae in the same person was 12±71 mg per minute. Men had a higher rate of sweat production than women (208±117 vs. 174±119 mg per minute, P=0.01). Age, body-mass index, smoking status, and the presence or absence of atopic diseases were not associated with sweat production. The mean rates of sweat production at base line were 165 mg per minute in the axilla assigned to

| TABLE 1. BASE-LINE CHARACTERISTICS OF THE 145 PATIENTS WHO COMPLETED 14 WEEKS OF FOLLOW-UP.* |
|-----------------|-----------------|
| VARIABLE        | VALUE           |
| Age (yr)        | 31.8±11.0       |
| Sex (M/F)       | 76/69           |
| Smoking status† |                  |
| Smoker          | 60              |
| Nonsmoker       | 85              |
| Body weight (kg)| 72.8±14.2       |
| Body-mass index‡| 23.8±3.4        |
| Size of hyperhidrotic area (cm²) | 48.5±25.4 |
| Rate of sweat production (mg/min) | 192±136  |

*Plus–minus values are means ±SD.
†Smoking status was reported by the patients at the time of enrollment.
‡Body-mass index is the weight in kilograms divided by the square of the height in meters.
treatment with botulinum toxin A and 174 mg per minute in the axillae assigned to placebo (P=0.15).

Two weeks after the initial injections, the mean rates of sweat production were 24±27 mg per minute in the axillae treated with botulinum toxin A and 144±113 mg per minute in the axillae treated with placebo (mean difference between the groups, 111 mg per minute; 95 percent confidence interval, 91 to 132; P<0.001) (Fig. 1). The decrease from base line of 30 mg per minute in the rate of sweat production in the axillae treated with placebo was also significant (P = 0.004). In 142 of the 145 patients (98 percent), the reduction in sweating was greater in the axilla treated with botulinum toxin A.

Two weeks after the injection of 100 U of botulinum toxin A into the axillae that had initially been treated with placebo, the mean rate of sweat production had decreased from 144±113 to 32±39 mg per minute (P<0.001) (Fig. 1). Twelve and 24 weeks after the 100-U injection, there were gradual increases in sweat production. The mean reduction in sweating two weeks after treatment with botulinum toxin A was 76.5 percent with 100 U, as compared with 81.4 percent with 200 U (P=0.04). When the two doses were compared in the 145 individual patients, 3 (2.1 percent) had equal reductions in sweating with the two doses, 64 (44.1 percent) had a greater reduction in sweating with 100 U, and 78 (53.8 percent) had a greater reduction with 200 U. Comparisons based on additional criteria and defined according to absolute or percentage reductions in sweating are shown in Table 2. Twenty-four weeks after the injection of 100 U of botulinum toxin A, the rates of sweat production (in the 136 patients in whom the rates were measured at that time) were still lower than the baseline values: 67±66 mg per minute in the axillae that had received 200 U and 65±64 mg per minute in the axillae that had received placebo and 100 U.

During the first 14 weeks of follow-up, no major adverse events were associated with treatment with botulinum toxin A. Temporary adverse effects included headache in four patients, muscle soreness of the shoulder girdle in two, increased facial sweating in one, and axillary itching in one. At four weeks after the initial injections, 118 patients (81.4 percent) rated their tolerance of treatment as excellent, 25 (17.2 percent) rated it as good, and 2 (1.4 percent) rated it as fair. Ninety-two patients (63.4 percent) reported that they were completely satisfied, 42 (29.0 percent) reported that they were satisfied, and 11 (7.6 percent) reported that they were partially satisfied; no one said that he or she was not satisfied. When asked whether they would recommend this treatment to others, 126 patients (86.9 percent) said that they would recommend

Figure 1. Mean (±SE) Rates of Sweat Production after Intradermal Injection of Botulinum Toxin A or Placebo.

At week 0, 200 U of botulinum toxin A was injected into one axilla in each patient and placebo into the other. At week 2, 100 U of botulinum toxin was injected into the axilla that had received placebo. Data were available for 145 patients at week 14 and for 136 at week 26. For the axillae that received 200 U of botulinum toxin A, the rate differed significantly (P<0.001) from the base-line rate throughout follow-up. For the axillae that initially received placebo, the value differed significantly from base line at week 2 (P=0.004); the changes from base line were also significant at weeks 4, 14, and 26, after the injection of 100 U of botulinum toxin A (P<0.001). Paired t-tests were used for all comparisons.
it in all cases, 16 (11.0 percent) that they would recommend it in most cases, and 2 (1.4 percent) that they would not recommend it; 1 patient (0.7 percent) did not respond to this question.

**DISCUSSION**

Hyperhidrosis, although it is not life-threatening, can have a substantial effect on the quality of life. Our multicenter study provides evidence of the efficacy and safety of intradermal botulinum toxin A injections in reducing focal axillary hyperhidrosis. We chose to use gravimetry to monitor the effects of treatment, since this method yields objective data and is easily reproducible. Other methods, such as the iodine–starch test or other staining procedures, are only semiquantitative.

Water-vapor analysis performed with the use of a detector over a flat skin surface after the injection of methacholine, the most accurate method of measuring maximal sweat production, is not feasible in the axillae. We are unaware of any representative epidemiologic data on what might be considered a normal rate of sweat production; an arbitrary definition of palmar hyperhidrosis as a rate of sweat production greater than 20 mg per minute according to gravimetric measurements has been proposed. We chose axillary rates of sweat production greater than 50 mg per minute to select patients with clinically evident axillary hyperhidrosis.

Our study confirms and extends the results of previous studies, which were limited to small series of patients treated in specialized institutions with diverse protocols. In our study, although the difference in outcomes between placebo and botulinum toxin A treatment was obvious, there was also a significant decrease in the mean rate of sweat production in the axilla treated with placebo. In statistical terms, this is readily explicable by regression to the mean in measurements obtained after we had selected a threshold value of sweat production. Since the injections of placebo and of 200 U of botulinum toxin A were given on the same occasion, it is possible that the axilla injected with placebo benefited from the contralateral injection as a result of the systemic spread of botulinum toxin A. Subclinical changes in the activity of distant muscles have been observed after intramuscular injection of botulinum toxin A for the treatment of dystonia. However, studies in which 400 U of botulinum toxin A (twice the dose we used in this study) was administered to only one axilla did not show any improvement in the untreated axilla according to gravimetry. Thus, subclinical spread of botulinum toxin A is an unlikely explanation for measurable changes in rates of sweat production.

Detailed dose–response curves for botulinum toxin A in humans have not been established either for the treatment of hyperhidrosis or for most other clinical uses of this drug. Botulinum toxin A is available in the United States as Botox (manufactured by Allergan, Irvine, Calif) and in Europe as Botox or Dysport (manufactured by Ipsen Biopharm, Wrexham, United Kingdom). In terms of clinical efficacy in humans, 1 U of Botox is estimated to be equal to 3 to 4 U of Dysport, the product used in our study. On the basis of previously reported clinical experience, 200 U of botulinum toxin A (Dysport), divided into 10 fractions, was chosen as the dose most likely to produce a satisfactory effect. We found little difference in the treatment effect seen with 200 U (81.4 percent reduction in sweat production) and that seen with 100 U (76.5 percent reduction). Comparison of the results two weeks after the initial injections must be interpreted cautiously, because of the effect of the placebo injections. The reductions in the rate of sweat production at four weeks (two weeks after the injection of 100 U of botulinum toxin A into the axillae that had received placebo), however, were similar in the two axillae. Follow-up measurements of the rates of sweat production showed no advantage to the higher dose.

For sustained relief from symptoms of hyperhidrosis, additional injections of botulinum toxin A at varying intervals are usually required. There are no explicit criteria for the dose and frequency of the subsequent treatments; according to previous reports, patients have requested additional injections 4 to 17 months after the first treatment. We found that although the mean rate of sweat production gradually increased after injection of botulinum toxin A, after six months it was still well below half the initial mean rate. The exact mechanisms of recurrent hyperhidrosis

**Table 2. Rate of Sweat Production and Outcomes Two Weeks After Treatment With Botulinum Toxin A or Placebo.**

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>200 U of BOTULINUM TOXIN A</th>
<th>100 U of BOTULINUM TOXIN A</th>
<th>PLACEBO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of sweat production</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤50 mg/min</td>
<td>126 (86.9)</td>
<td>120 (82.8)</td>
<td>7 (4.8)</td>
</tr>
<tr>
<td>&lt;25 mg/min</td>
<td>94 (64.8)</td>
<td>90 (62.1)</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>0 mg/min</td>
<td>7 (4.8)</td>
<td>10 (6.9)</td>
<td>0</td>
</tr>
<tr>
<td>Reduction in sweating</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥25%</td>
<td>138 (95.2)</td>
<td>129 (89.0)</td>
<td>22 (15.2)</td>
</tr>
<tr>
<td>≥50%</td>
<td>134 (92.4)</td>
<td>129 (89.0)</td>
<td>22 (15.2)</td>
</tr>
<tr>
<td>≥75%</td>
<td>114 (78.6)</td>
<td>99 (68.3)</td>
<td>4 (2.8)</td>
</tr>
<tr>
<td>Combined outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥25% and ≤50 mg/min</td>
<td>126 (86.9)</td>
<td>119 (82.1)</td>
<td>5 (3.4)</td>
</tr>
<tr>
<td>&lt;25% and &gt;50 mg/min</td>
<td>7 (4.8)</td>
<td>6 (4.1)</td>
<td>93 (64.1)</td>
</tr>
</tbody>
</table>

*P < 0.001 for all comparisons between 200 U of botulinum toxin A and placebo and between 100 U of botulinum toxin A and placebo. P = 0.1 for all comparisons between 200 U and 100 U except for the number of patients with a 75 percent reduction in sweating (P = 0.03). The McNemar test was used for all comparisons.

**BOTOULINUM TOXIN A FOR AXILLARY HYPERHIDROSIS (EXCESSIVE SWEATING)**

after intradermal injection of botulinum toxin A are unknown. It has been consistently shown that new nerve endings grow within three months after intramuscular injection of botulinum toxin A; however, sympathectomy nerve endings that innervate the sweat glands have not been studied. Resistance to botulinum toxin A occurs in up to 5 percent of patients with dystonia and has been attributed to the induction of antibodies against botulinum toxin A. We did not observe resistance to botulinum toxin A in our study, nor are we aware that has been observed in other studies of patients with hyperhidrosis.

We conclude that intradermal injection of botulinum toxin A is a safe, effective, and well-tolerated treatment for axillary hyperhidrosis and should be considered for patients who do not have a response to topical treatment.

Supported by Ipsen-Pharma, Erlangen, Germany; Dr. Heckmann and Dr. Ceballos-Baumann have received honorariums for speeches from Ipsen-Pharma and from other companies that manufacture botulinum toxin.

We are indebted to K. Dieterich, Ph.D., C. Hautmann, M.D., and I. Marf, Ph.D., for management; to D. Schwenner, Ph.D., for statistical analysis (at the Gesellschaft für Therapieforschung, Munich, Germany); and to B. Rzany, M.D., for valuable discussions.

APPENDIX

The Hyperhidrosis Study Group includes the following (listed in alphabetical order): Dermatologische Klinik, Krankenhaus Berlin-Spandau (G. Albrecht and A. Harrel); Klinik und Poliklinik für Dermatologie, Rheinische Friedrich-Wilhelms-Universität, Bonn (T. Bieber, R. Gerdsen, and W. Petrow); Hautklinik, Städtische Klinikum Dortmund (U. Biechtel, P. Frosch, and A. Magert); Klinik und Poliklinik für Dermatologie, Carl Gustav Carus Universität, Dresden (G. Sebastian and M. Stein); Hautklinik der Heinrich-Heine-Universität, Düsseldorf (A. Rumlich and T. Ruzicka); Haut- und Geschlechtskrankheiten, Universität Würzburg (H. Hamm and G. Gross); Universitäts-Hautklinik, Ulm (S. Breit, M. Dendorfer, G. Kick, M. Schaller, and B. Wörle); Klinik und Poliklinik für Dermatologie und Venerologie, Universität Regensburg (S. Karrer and R. M. Petrow); Hautklinik, Städtische Kliniken Dortmund (U. Biechtel, P. Frosch, and A. Magert); Klinik und Poliklinik für Dermatologie, Universität zu Köln (C. Sacher); Klinik und Poliklinik für Hautkrankheiten, Universität Leipzig (B. Haupt, U. F. Hausen, and P. Neophot); Klinik für Dermatologie und Venerologie, Universitätshäusl, München (H. Durr); Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln (E. Sacher); Klinik und Poliklinik für Hautkrankheiten, Universität Leipzig (B. Haupt, U. F. Hausen, and P. Neophot); Klinik für Dermatologie und Venerologie, Universitätshäusl, München (H. Durr); Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln (E. Sacher); Klinik und Poliklinik für Dermatologie, Universität Regensburg (S. Karrer and R. M. Szczepski); Klinik und Poliklinik für Dermatologie und Venerologie, Universität Regensburg (B. Ehlers and G. Gross); Universitäts-Hautklinik, Ulm (P. Gortlober, R.U. Peter, and M. Steincr); Klinik und Poliklinik für Haut- und Geschlechtskrankheiten, Universität Würzburg (H. Hamm and S. Ricker); and Dermatologische Klinik, Universitätsspital Zürich (R. Boni, G. Burg, B. Heidecker, and O. Kreyden).

REFERENCES